These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 21159705)

  • 1. Economic impact of enoxaparin after acute ischemic stroke based on PREVAIL.
    Pineo G; Lin J; Stern L; Subrahmanian T; Annemans L
    Clin Appl Thromb Hemost; 2011 Apr; 17(2):150-7. PubMed ID: 21159705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: a hospital perspective of the PREVAIL trial.
    Pineo G; Lin J; Stern L; Subrahmanian T; Annemans L
    J Hosp Med; 2012 Mar; 7(3):176-82. PubMed ID: 22058011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis.
    Amin AN; Lin J; Lenhart G; Schulman KL
    Thromb Haemost; 2009 Aug; 102(2):321-6. PubMed ID: 19652883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism.
    Deitelzweig SB; Becker R; Lin J; Benner J
    Thromb Haemost; 2008 Nov; 100(5):810-20. PubMed ID: 18989525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study.
    Kase CS; Albers GW; Bladin C; Fieschi C; Gabbai AA; O'Riordan W; Pineo GF;
    Stroke; 2009 Nov; 40(11):3532-40. PubMed ID: 19696423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low molecular weight heparins in the prevention of venous thromboembolism in nonsurgical patients.
    Haas S
    Semin Thromb Hemost; 1999; 25 Suppl 3():101-5. PubMed ID: 10549724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of venous thromboembolism, recurrent stroke, and other vascular events after acute ischemic stroke: the role of low-molecular-weight heparin and antiplatelet therapy.
    Sherman DG
    J Stroke Cerebrovasc Dis; 2006; 15(6):250-9. PubMed ID: 17904084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term therapy with enoxaparin or unfractionated heparin for venous thromboembolism in hospitalized patients: utilization study and cost-minimization analysis.
    Argenta C; Ferreira MA; Sander GB; Moreira LB
    Value Health; 2011; 14(5 Suppl 1):S89-92. PubMed ID: 21839908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of the use of enoxaparin in non-ST-elevation acute coronary syndrome.
    Nutescu EA; Steinmetz Pater K
    Expert Opin Pharmacother; 2008 Jan; 9(1):95-105. PubMed ID: 18076341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When innovative therapies make economic sense: economic analysis of enoxaparin versus unfractionated heparin in the ESSENCE trial--an overview. Efficacy and Safety of Subcutaneous in non-Q Wave Coronary Events.
    Mark D
    Can J Cardiol; 1998 Aug; 14 Suppl E():24E-27E. PubMed ID: 9779030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and economic outcomes with appropriate or partial prophylaxis.
    Amin AN; Lin J; Johnson BH; Schulman KL
    Thromb Res; 2010 Jun; 125(6):513-7. PubMed ID: 19931121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
    Stellbrink C; Nixdorff U; Hofmann T; Lehmacher W; Daniel WG; Hanrath P; Geller C; Mügge A; Sehnert W; Schmidt-Lucke C; Schmidt-Lucke JA;
    Circulation; 2004 Mar; 109(8):997-1003. PubMed ID: 14967716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
    Holzheimer RG
    Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada.
    Diamantopoulos A; Lees M; Wells PS; Forster F; Ananthapavan J; McDonald H
    Thromb Haemost; 2010 Oct; 104(4):760-70. PubMed ID: 20806107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of venous thromboembolism in the rehabilitation phase after spinal cord injury: prophylaxis with low-dose heparin or enoxaparin.
    Spinal Cord Injury Thromboprophylaxis Investigators
    J Trauma; 2003 Jun; 54(6):1111-5. PubMed ID: 12813331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease.
    Kleber FX; Witt C; Vogel G; Koppenhagen K; Schomaker U; Flosbach CW;
    Am Heart J; 2003 Apr; 145(4):614-21. PubMed ID: 12679756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of enoxaparin as prophylaxis against venous thromboembolism in seriously ill medical patients: a US perspective.
    de Lissovoy G; Subedi P
    Am J Manag Care; 2002 Dec; 8(12):1082-8. PubMed ID: 12500884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost in the use of enoxaparin compared with unfractionated heparin in patients with atrial fibrillation undergoing a transesophageal echocardiography-guided cardioversion (from Assessment of Cardioversion using Transesophageal Echocardiography [ACUTE] II randomized multicenter study).
    Zhao L; Zhang Z; Kolm P; Jasper S; Lewis C; Klein A; Weintraub W;
    Am J Cardiol; 2008 Feb; 101(3):338-42. PubMed ID: 18237596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.